OBR Daily Commentary

forumImage

Studies Back Salvage RT After Prostatectomy

(MedPage Today) Sept 28, 2020 - Three randomized trials and a meta-analysis of the trials failed to show a significant effect on biochemical progression or combined clinical events after radical prostatectomy for early, high-risk prostate cancer.

Read Article arrow

Howard Sandler, MD, MS, FASTRO (Posted: September 29, 2020)

quotesMultiple randomized trials comparing adjuvant RT after radical prostatectomy (with undetectable PSA) vs. early salvage (when the PSA becomes detectable). The PIs of each study agreed in advance to combine data in a meta-analysis. So far, it looks like early salvage is acceptable although the largest study, RADICALS, has not presented the primary endpoint of the study. As the editorial notes, the patients were pretty low risk. For high risk patients, adjuvant RT should still be considered -- many patients have a predicted risk of failure of >50%. Observing them is probably not ideal.quotes

Add Comment 1 Comment
forumImage

Radiotherapy Can Be Used In Hard-to-treat Bladder Cancer

(ICR [UK]) Jan 13, 2020 - More targeted forms of radiotherapy can effectively treat bladder cancer which has spread to the lymph nodes of the pelvis, according to a new clinical trial.

Read Article arrow

Howard Sandler, MD, MS, FASTRO (Posted: January 13, 2020)

quotesRadiotherapy as primary treatment (along with TUR and chemotherapy) is having a bit of a renaissance. The BC2001 study, using 5FU and mitomycin along with radiation, demonstrated a non-cisplatin regimen can be effective. Recently published RTOG 0712 (Coen JJ JCO 2019) showed that single agent gemcitabine can be used. Finally, SWOG/NRG have a large open bladder preserving trial testing whether bladder intact survival can be enhanced with immune checkpoint inhibition. Promising times for bladder preservation!quotes

Add Comment 1 Comment
forumImage

F.D.A. Nominee Clears Senate Panel

(New York Times) Dec 3, 2019 - A Senate committee on Tuesday advanced the nomination of Dr. Stephen Hahn, a noted radiologist and cancer researcher, to lead the Food and Drug Administration. Dr. Hahn, chief medical executive at the University of Texas M.D. Anderson Cancer Center, was nominated by President Trump last month to replace Dr. Scott Gottlieb, who left the job in April.

Read Article arrow

Howard Sandler, MD, MS, FASTRO (Posted: December 03, 2019)

quotesSteve Hahn is very well regarded in the ASTRO community. He's a radiation oncologist who is also board-certified in medical oncology. He's been chair of rad onc at UPenn and a leader at MD Anderson. The radiation oncology community is excited for Steve as his nomination proceeds thru the regulatory process and we hope that he's confirmed as the next FDA Commissioner.quotes

Add Comment 1 Comment

Meet the Editorial Board

Prostate Cancer
member photo
Tomasz M. Beer, MD, FACP

Professor of Medicine, Division of Hematology/Medical O...

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Associate Clinical Professor, Medical Oncology Executi...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Distinguished Professor of Medicine, Rutgers Robert Woo...

Radiation Oncology
member photo
Howard Sandler, MD, MS, FASTRO

Ronald H. Bloom Chair in Cancer Therapeutics Professo...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Steven Spielberg Family Chair in Hematology Oncology P...

member photo
Stephen M. Schleicher, M.D., MBA

Community Oncology, Medical Oncologist, OneOncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...